H.C. Wainwright raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $93 from $84 and keeps a Buy rating on the shares. The firm notes that another very strong topline revenue performance was reflected in its Q2 results. Key to the strong 2Q25 results was the above consensus Cortrophin revenue figure of $81.6M, 66% year over year growth from Q2 2024, and up 54% sequentially from Q1 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler
- Morning Movers: Under Armour sinks following second quarter earnings
- ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42
- ANI Pharmaceuticals raises FY25 adj. EPS view to $6.98-$7.35 from $6.27-$6.62
- Is ANIP a Buy, Before Earnings?